^
Association details:
| Biomarker: | EML4-ALK variant 1 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
Published date:
03/10/2023
Excerpt:
A clinically meaningful improvement in investigator-assessed PFS was also observed in the lorlatinib group compared with the crizotinib group (HR = 0.24, 95% CI: 0.14–0.41) (Fig. 2B)....Overall, 80% of patients with an objective response in the lorlatinib group and 29% in the crizotinib group had a duration of response (DOR) of at least 12 months....ORRs were numerically higher in the lorlatinib arm than the crizotinib arm in patients with EML4::ALK variant 1 (100% [95% CI: 54–100].
DOI:
10.1016/j.jtocrr.2023.100499
Trial ID:
Source:
Title:
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Published date:
05/26/2022
Excerpt:
Based on ctDNA, ORRs were generally higher in the lorlatinib vs crizotinib arm, reaching 80% and 72% for EML4-ALK v1 and v3, respectively, in the lorlatinib arm, and 50% and 74% in the crizotinib arm....Pts with untreated ALK+ advanced NSCLC had higher ORRs and potentially longer PFS across predefined biomarker subgroups when treated with lorlatinib compared with crizotinib in the phase 3 CROWN study.
DOI:
10.1200/JCO.2022.40.16_suppl.9070
Trial ID:
Source:
Title:
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations
Published date:
08/02/2023
Excerpt:
ORRs were numerically higher with lorlatinib vs crizotinib for EML4::ALK variant 1 (v1; 80.0% vs 50.0%) and variant 2 (v2; 85.7% vs 50.0%), but were similar between the arms for variant 3 (v3; 72.2% vs 73.9%).
DOI:
https://doi.org/10.1016/j.jtho.2023.07.023
